Tackling fibrosis: Galecto raises $64m in equity financing
Galecto is focused on developing innovative drugs for fibrosis-associated diseases, including IPF and NASH. Credit: Nephron via Wikimedia.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more